Latest Options News

Litchfield Minerals has raised $6 million from top-tier institutional investors to accelerate exploration at its promising Oonagalabi copper-zinc prospect in Australia's Northern Territory.

BCAL Diagnostics has established a $10 million convertible note facility, with $5 million already committed, to accelerate its cancer detection technologies and commercial milestones.

Zip Co Limited has reported a near doubling in cash earnings for Q1 FY26, driven by robust transaction growth and improved operating leverage, particularly in the US market. The company also doubled its share buy-back program and raised its US transaction volume growth guidance.

Black Cat Syndicate reports visible antimony mineralisation in initial drill holes at Mt Clement, advancing one of Australia’s largest antimony deposits with assays due in November 2025.

Podium Minerals has achieved a metallurgical breakthrough at its Parks Reef project, delivering an 80% recovery of key metals and a 50-fold concentrate grade upgrade. The company is advancing a A$12 million capital raise to accelerate development amid soaring platinum and palladium prices.

Botanix Pharmaceuticals reports a strong start to FY26 with a 50% surge in Sofdra prescriptions and a 65% rise in net revenue, underpinned by a larger sales team and operational efficiencies.

Castile Resources has significantly increased its Mineral Resource Estimate for the Rover 1 Project, reflecting higher gold, copper, bismuth, and cobalt prices. This update enhances the project's scale and potential revenue streams as it advances through its Bankable Feasibility Study.

Duketon Mining reports promising gold assay results from its first drilling at Killarney, secures an option to acquire the Boodanoo Gold Project, and updates nickel resource estimates at Rosie and C2 deposits.

Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows promising response rates in first line non-small cell lung cancer, especially in patients with low or no PD-L1 expression.

Immutep Limited’s Phase II trial of eftilagimod alfa combined with radiotherapy and KEYTRUDA in soft tissue sarcoma patients has exceeded its primary endpoint, showing a 51.5% median tumor hyalinization rate, more than triple the historical standard. These promising results, presented at ESMO 2025, suggest a potential breakthrough in a challenging cancer indication.

Turners Automotive Group has updated its dividend announcement, revealing a fully franked ordinary dividend and detailing the strike price for its Dividend Reinvestment Plan.

BlackRock Investment Management (Australia) Limited has announced final cash distributions for its iShares Balanced ESG ETF and High Growth ESG ETF, detailing payment schedules and reinvestment options for investors.